Goldman Neutral On Cardinal Health, $47 PT

Goldman Sachs rated Cardinal Health (NYSE: CAH) neutral with a 12-month price target of $47.

“Overall, we sense no change in tone at CAH and continue to like the Wholesaler momentum through the generic wave, but we remain Neutral on CAH, as we see greater upside potential elsewhere at this point. There is no change to Neutral rating or $47, 12-month price target,” Goldman said in a note.